New 52 Week Low Today

Editas Medicine Inc EDIT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:56 PM EDT
5.32quote price arrow up+0.10 (+1.91%)
Volume
43,165
Close
5.22quote price arrow down-0.13 (-2.43%)
Volume
1,496,319
52 week range
5.11 - 11.91
Loading...
  • Open5.27
  • Day High5.27
  • Day Low5.11
  • Prev Close5.35
  • 52 Week High11.91
  • 52 Week High Date06/14/23
  • 52 Week Low5.11
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap429.265M
  • Shares Out82.23M
  • 10 Day Average Volume1.78M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change-48.47

KEY STATS

  • Open5.27
  • Day High5.27
  • Day Low5.11
  • Prev Close5.35
  • 52 Week High11.91
  • 52 Week High Date06/14/23
  • 52 Week Low5.11
  • 52 Week Low Date04/25/24
  • Market Cap429.265M
  • Shares Out82.23M
  • 10 Day Average Volume1.78M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change-48.47

RATIOS/PROFITABILITY

  • EPS (TTM)-2.06
  • P/E (TTM)-2.54
  • Fwd P/E (NTM)-1.99
  • EBITDA (TTM)-163.116M
  • ROE (TTM)-43.17%
  • Revenue (TTM)78.123M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-196.13%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/03/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Editas Medicine Inc

 

Profile

MORE
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1)...
Emma Reeve
Independent Chairman of the Board
Gilmore O Neill
President, Chief Executive Officer, Director
Erick Lucera
Chief Financial Officer, Executive Vice President
Bruce Eaton Ph.D.
Executive Vice President
Linda Burkly Ph.D.
Executive Vice President, Chief Scientific Officer
Address
11 Hurley St
Cambridge, MA
02141-2110
United States

Top Peers

SYMBOLLASTCHG%CHG
URGN
Urogen Pharma Ltd
13.82-0.39-2.74%
TBPH
Theravance Biopharma Inc
9.14-0.03-0.33%
ADCT
ADC Therapeutics SA
4.44-0.34-7.11%
ALEC
Alector Inc
4.81-0.44-8.38%
FATE
Fate Therapeutics Inc
3.87-0.43-10.00%